Barzaghi N, Gatti G, Crema F, Monteleone M, Amione C, Leone L, Perucca E
Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Br J Clin Pharmacol. 1987 Dec;24(6):836-8. doi: 10.1111/j.1365-2125.1987.tb03257.x.
The serum levels of carbamazepine (CBZ) and its 10,11-epoxide metabolite (CBZ-E) were determined in seven subjects after a single dose of CBZ (400 mg) in the control state and during co-administration of erythromycin (500 mg three times daily for 10 days). Erythromycin treatment was associated with a decrease in CBZ clearance and a prolongation of CBZ half-life, while CBZ-E levels were markedly reduced. These data provide evidence that erythromycin inhibits the conversion of CBZ to its epoxide metabolite.
在7名受试者中,测定了他们在对照状态下单次服用卡马西平(CBZ,400mg)以及在联合使用红霉素(每日3次,每次500mg,共10天)期间血清中卡马西平(CBZ)及其10,11 - 环氧化代谢物(CBZ - E)的水平。红霉素治疗与卡马西平清除率降低及卡马西平半衰期延长有关,而CBZ - E水平则显著降低。这些数据证明红霉素可抑制卡马西平向其环氧化代谢物的转化。